id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-5381-0001,FDA,FDA-2024-N-5381,Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence,Notice,Announcement,2024-12-27T05:00:00Z,2024,12,2024-12-27T05:00:00Z,,2024-12-27T16:47:11Z,2024-30776,0,0,090000648689153c